Michael Anstey

Michael Anstey is a Partner at Cambridge Innovation Capital based in Cambridge, United Kingdom, where he specializes in seed and Series A life sciences and healthcare investments. At the firm, which has raised over £0.6 billion and supported approximately 40 companies since 2014, he manages portfolio investments including NASDAQ-listed Bicycle Therapeutics, Nuclera, and Epitopea. Prior to his current role, he served as a Principal in the Health Care Practice Area at Boston Consulting Group and worked as an Investment Analyst at Oxford Capital Partners. He holds a DPhil in Zoology from the University of Oxford and previously co-founded an early-stage biotechnology company focused on small molecule drugs targeting protein-protein interactions. Anstey currently focuses on bridging scientific research and venture capital to advance precision-guided therapies and biotechnology innovation across the Greater Cambridge ecosystem.